CD274 and neoplasm: More efforts should be devoted to evaluating novel biomarkers for predicting response to ICIs in TNBC patients, such as PD-L1 expression, tumor mutational burden, microsatellite instability status, etc. (39) Recent clinical trials have demonstrated the benefits of various immune-based combinations for metastatic TNBC patients; thus chemoimmunotherapy has been approved as a new first-line treatment option for metastatic TNBC patients with elevated CPS or PD-L1 overexpression.